An interventional study of Mainstream Genetic Testing Model and Enhanced Standard of Care Model in Hereditary Cancer Syndrome, sponsored by University of Illinois at Chicago. Recruiting at 1 site in United States. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Neoplastic Syndromes, Hereditary with a site in United States — 19 open to participants now, 21 under way, none of them phase 3. Neoplastic Syndromes, Hereditary · United States.
Among the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States, this one is the 16th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2022, is one of 17 with no phase, reaches primary completion later than 1 of the 18 other live ones, and was the 20th registered.
47 studies on the registry are indexed under Neoplastic Syndromes, Hereditary; 26 are open to participants now.
Browse Neoplastic Syndromes, Hereditary studies →19 of the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 21–75 · Women only
Columbia University · Sites in United States
Ages 18–55 · Women only · Healthy volunteers
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
Weill Medical College of Cornell University · Sites in United States
Ages 18–55 · Women only
Shwachman-Diamond Syndrome Alliance Inc · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Neoplastic Syndromes, Hereditary studies recruiting now, 11 (55%) set no upper age limit and 6 (30%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 25 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 545 across 23 interventional studies indexed under Neoplastic Syndromes, Hereditary.
Median enrollment 588 across the 18 interventional studies, 1,000 across the 15 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 33 have an industry lead sponsor. The 10 most frequent:
University of Illinois at Chicago is the lead sponsor of 496 studies on the registry; 115 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
University of Illinois at Chicago has 1 study filed under Neoplastic Syndromes, Hereditary — fewer than ten, so there is no comparison to draw.
5 of the studies in Neoplastic Syndromes, Hereditary with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05664867University of Illinois at ChicagoImplementation of Population Cancer Genetic Services in Federally Qualified Health Centers (FQHC) | 2026-12 |
| NCT06096688Weill Medical College of Cornell UniversityDiscovering New Targets for Colorectal and Endometrial Cancer Risk Reduction | 2026-12-31 |
| NCT06654466Nest GenomicsClosing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer | 2027-03 |
| NCT07052266Weill Medical College of Cornell UniversityTrial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening | 2027-06 |
| NCT07053813University of WashingtonApplying Population Management Best Practices to Preventative Genomic Medicine Trial | 2027-07-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is for researchers to compare the effectiveness of a mainstreamed model of genetic testing (MGT) with an enhanced standard of care model (SOC+) on the uptake of genetic testing among at-risk patients in an urban Federally Qualified Health Center (primary care) setting using a hybrid-effectiveness study design.
Aim 1 is to compare the effectiveness of MGT and SOC+ interventions on the uptake of genetic testing among patients receiving primary care in an urban federally qualified health center (FQHC) system using a randomized trial study design. The hypothesis is that the uptake of testing will be higher among patients receiving services through the MGT compared with the SOC+ model.
Aim 2 is to evaluate the implementation outcomes (acceptability, feasibility and sustainability) and the barriers and facilitators of cancer genetic service delivery approaches within primary care at FQHCs via qualitative interviews with patients, primary care providers and clinic staff, and organizational leaders, guided by the Explore, Prepare, Implement, Sustain (EPIS) implementation framework.
The study will take place at four community health clinics that are part of a Federally Qualified Health Center (FQHC) network in Chicago. Each clinic will use one of two ways of providing cancer genetic services: an enhanced standard of care model that includes patient navigation support (SOC+), or a mainstream genetic testing model (MGT) in which primary care providers offer testing directly. Information such as patients' demographic characteristics, referrals for genetic counseling, completion of genetic testing, and how long it takes to complete testing will be collected from clinic records. Patients, healthcare providers, and clinic staff will also be invited to take part in interviews to share their experiences and perspectives on how each model worked in practice.
More than 15 years after the release of evidence-based guidelines recommending hereditary cancer risk assessment and testing for at-risk individuals, fewer than one in five eligible patients receive this care. Utilization of cancer genetic services remains substantially lower among racial and ethnic minority populations. Addressing inequities in access to these services is essential, as approximately 10 to 15 percent of cancers are linked to inherited mutations, and early identification of high-risk individuals can support prevention and early detection strategies that reduce disparities in cancer outcomes.
Multiple social determinants of health (SDoH) contribute to limited access to genetic services among underserved populations. At the clinic level, many community health centers have limited capacity to systematically identify at-risk patients, employ few or no genetic specialists, and must rely on external systems for genetic counseling and testing. At the provider level, primary care clinicians often report low confidence and limited training in cancer genetics, while genetic specialists may have limited presence or integration in these care settings. At the patient level, structural, economic, and cultural barriers continue to restrict engagement in genetic testing and counseling.
This project will evaluate and compare two models of cancer genetic service delivery in primary care to improve equitable access among patients served by Federally Qualified Health Centers (FQHCs). The enhanced standard of care model (SOC+) uses universal electronic hereditary cancer risk assessment (HCRA) to identify eligible patients, combined with patient navigation to address individual barriers such as financial concerns and literacy needs. The mainstream genetic testing model (MGT) embeds genetic testing directly into primary care visits, allowing patients to receive education, counseling, and test ordering from their primary care provider without referral to specialty care.
Aim 1: Compare the effectiveness of MGT and SOC+ on uptake of genetic testing among minority patients receiving primary care within an urban FQHC system.
Aim 2: Evaluate implementation outcomes (acceptability, feasibility, and sustainability) and identify barriers and facilitators to cancer genetic service delivery in primary care using qualitative interviews with patients, providers, and clinic staff, guided by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework.
A quasi-experimental design will be used across four FQHC clinics, with each clinic assigned to one of the two models, two SOC+ and two MGT. Demographic and service utilization data, including referrals, testing completion, and time-to-test intervals, will be collected from the electronic medical record. Semi-structured interviews with patients, providers, and staff will further explore experiences and perceptions of each model.
This work will generate actionable evidence on scalable and sustainable approaches to delivering guideline-based genetic services in underserved primary care settings. Findings will inform best practices to reduce inequities in access to precision cancer prevention and early detection services.
Aim 1 and 2 Inclusion Criteria for patients
Exclusion Criteria:
Aim 2
Inclusion Criteria for Providers/Staff:
Exclusion Criteria:
1. Does not meet inclusion criteria above
The mainstream genetic testing (MGT) model of cancer genetic services involves a non-genetics healthcare provider, such as the primary care provider, who engages patients in the counseling, consenting, and ordering of genetic testing. The provider/care team discloses the genetic test results and refers patients for genetic counseling only when genetic test results are abnormal. By eliminating the pre- and post-test counseling visits with a genetics provider, the MGT model has the potential to provide scalable access to genetic services.
Other: Mainstream Genetic Testing Model
The enhanced standard of care model (SOC+) is the current referral model of cancer genetic services delivery with an enhancement to include screening for and resources to address health literacy. This model begins with a health care provider's recognition, identification and then referral of a patient to a genetic counselor where genetic testing takes place if appropriate. This model is time- and resource- intensive and may not be scalable.
Other: Enhanced Standard of Care Model
Mainstream Genetic Testing Model of Cancer Genetics Service Delivery
Also known as: MGT
Enhanced Standard of Care Model of Cancer Genetic Service Delivery
Also known as: SOC+
Uptake of genetic testing
compare the uptake of genetic testing among patients in both models of cancer genetic delivery who screen positive on hereditary cancer risk asserssment (HCRA)
Time frame: 2 years
Time to genetic testing
Time from screening positive on HCRA to genetic testing
Time frame: 2 years
Evaluate the implementation outcomes (acceptability, feasibility and sustainability) and the barriers and facilitators of cancer genetic service delivery approaches within primary care at FQHCs
Qualitative interviews with patients and providers in the clinical trial, guided by the Explore, Prepare, Implement, Sustain (EPIS) implementation framework.
Time frame: 2 years
Started Aug 2022 (actual). Primary completion is estimated for Dec 2026, 52 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neoplastic Syndromes, Hereditary →
University of Illinois at Chicago →